1. List of adverse events in oral (systemic) administration of everolimus (rapalog).

Adverse events	Everolimus (n = 157)	Placebo (n = 78)
Stomatitis	69 (44%)	12 (15%)
Nasopahryngitis	33 (21%)	21 (27%)
Acne‐like skin lesions	17 (11%)	2 (3%)
Rash	9 (6%)	2 (3%)
Convulsion	22 (14%)	12 (15%)
Pyrexia	22 (14%)	6 (8%)
Headache	17 (11%)	8 (10%)
Cough	26 (17%)	9 (12%)
Hypercholesterolaemia	16 (10%)	1 (1%)
Aphthous stomatitis	17 (11%)	4 (5%)
Fatigue	25 (16%)	8 (10%)
Mouth ulceration	41(26%)	4 (5%)
Nausea	13(8%)	5 (6%)
Urinary tract infection	12(8%)	6 (8%)
Bronchitis	11(7%)	5 (6%)
Otitis media	9 (6%)	3 (4%)
Pharyngitis	8 (5%)	1 (1%)
Vomiting	26 (17%)	7 (9%)
Anaemia	10 (6%)	1 (1%)
Arthralgia	10 (6%)	2 (3%)
Diarrhoea	20 (13%)	4 (%)
Abdominal pain	9 (6%)	4 (5%)
Blood lactate dehydrogenase increased	9 (6%)	2 (3%)
Hypophosphataemia	9 (6%)	0 (0%)
Eczema	8 (5%)	3 (4%)
Leucopenia	8 (5%)	3 (4%)
Oropharyngeal pain	8 (5%)	4 (5%)
Upper respiratory tract infection	21 (13%)	9 (12%)

Data were analysed from two studies (Bissler 2013; Franz 2013).